A study to investigate subcutaneous trastuzumab administration at home with a Single Injection Device in patients with HER2-positive early breast cancer.
- Registry ID
- EUCTR2013-000829-31
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Roche Nederland B.V.
- Start date
- 2013-09-24
- Completion date
- 2018-09-14
- Last update
- 2026-08-16
Conditions
- HER2-positive early breast cancer
Summary
To assess the overall safety and tolerability of subcutanous (SC) trastuzumab in HER2-positive early breast cancer (EBC) patients with using a single-use injection device (SID).
Locations
View on source registry